Cefazolin

證據等級: L5

預測適應症: 10 個

Cefazolin: From Surgical Infection Prophylaxis to Infectious Otitis Media

One-Sentence Summary

Cefazolin is a first-generation cephalosporin antibiotic widely used in clinical practice for surgical site infection prophylaxis and treatment of susceptible bacterial infections. The TxGNN model predicts it may be effective for Infectious Otitis Media, with 1 clinical trial and 3 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Surgical prophylaxis and susceptible bacterial infections (no ARTG registration data available)
Predicted New Indication	Infectious Otitis Media
TxGNN Prediction Score	99.44%
Evidence Level	L3
Australia Market Status	Not registered (0 ARTG entries returned)
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Cefazolin is a first-generation cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis through irreversible binding to penicillin-binding proteins (PBPs). It demonstrates strong activity against Staphylococcus aureus (MSSA), Streptococcus pyogenes, and partial activity against Streptococcus pneumoniae, with limited coverage of Gram-negative organisms.

Acute infectious otitis media (AOM) is commonly caused by S. pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Cefazolin’s activity against S. pneumoniae and S. aureus provides partial pathogen coverage, supporting the mechanistic basis for the TxGNN prediction. In scenarios where S. aureus is the implicated pathogen — such as otitis media arising as a complication of post-surgical ear infections or furunculosis — Cefazolin’s antimicrobial spectrum is well-suited to the clinical need.

The key limitation is that Cefazolin lacks meaningful activity against H. influenzae and M. catarrhalis, which together account for approximately 40–50% of bacterial AOM in children. This constrains its utility as empiric monotherapy for infectious otitis media and restricts any potential role to pathogen-confirmed or procedure-related contexts. The overall mechanistic fit is therefore rated as moderate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01511107	Phase 2b	Terminated	520	Multicentre double-blind RCT in children aged 6–23 months comparing 5-day (reduced-duration) versus 10-day (standard-duration) antibiotic therapy for AOM. Trial was terminated prior to completion; reason not specified in available records. Results should be interpreted with caution.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
877649	1977	Review	South Med J	Narrative review of cephalosporin antibiotics in paediatric infections including otitis media; discusses antimicrobial spectrum, safety profile, and clinical utility of first-generation cephalosporins in children
39567876	2025	Case Series	Ann Otol Rhinol Laryngol	Describes empiric ceftazidime–Cefazolin combination therapy in paediatric Gradenigo Syndrome (petrous apicitis as an AOM complication); illustrates direct clinical application of Cefazolin in an otitis media-related condition
3742953	1986	Case Series	Clin Pharm	Case report of Stevens-Johnson syndrome in a child receiving sequential antibiotic therapy for otitis media; peripheral relevance to Cefazolin use in the AOM treatment pathway

Australia Market Information

No ARTG entries for Cefazolin were identified in the TGA database query. Clinicians should verify current registration status directly via the TGA ARTG public search, as injectable Cefazolin formulations may be registered under different trade names or sponsor listings not captured by this query.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although TxGNN assigns a high prediction score (99.44%) for infectious otitis media, the supporting clinical evidence base is limited — the sole registered clinical trial was terminated before completion, and available literature consists of older narrative reviews and case reports with only indirect relevance to Cefazolin as a treatment for AOM. The significant antimicrobial spectrum gap against H. influenzae and M. catarrhalis further constrains Cefazolin’s applicability as empiric therapy for standard infectious otitis media.

To proceed, the following is needed:

Investigation of the reason for early termination of NCT01511107 (efficacy failure, safety signal, or operational factors) to determine whether the hypothesis remains viable
Identification of specific AOM subpopulations where Cefazolin’s spectrum aligns with likely pathogens (e.g., confirmed MSSA or S. pneumoniae otitis media; post-operative middle ear infections)
Verification of current TGA/ARTG registration status for Cefazolin products available in Australia
Retrieval of full TGA Product Information including contraindications, warnings, and drug interactions to complete the safety profile
Higher-priority repurposing opportunity: The Urinary Tract Infection indication (Rank #10, TxGNN score 98.91%, Evidence Level L3, Decision: Proceed with Guardrails) presents a substantially stronger repurposing case — 11 registered clinical trials, 20 publications including a completed RCT directly comparing Cefazolin versus ceftriaxone for complicated UTI (PMID 40033251) and a systematic review supporting first-generation cephalosporins for uncomplicated UTI (PMID 32659466). A dedicated report for this indication is recommended as the priority next step.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.